| Acute Leukemia |
1 |
1 |
| Escherichia coli |
0 |
0.99 |
| Acute Lymphoblastic Leukemia |
0 |
0.95 |
| Thrombus |
0 |
0.27 |
| Blood |
0 |
0.25 |
| Child |
0 |
0.25 |
| Food and Drug Administration (FDA) |
0 |
0.9 |
| Leukemia |
0 |
0.25 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.75 |
| Lymphoblastic Lymphoma |
0 |
0.8 |
| Pediatric Oncology |
0 |
0.18 |
| Adverse Effects |
0 |
0.13 |
| Bacteria |
0 |
0.13 |
| Cancer |
0 |
0.13 |
| Chemotherapy |
0 |
0.13 |
| Contraception |
0 |
0.13 |
| Dermatitis |
0 |
0.13 |
| Hemorrhage |
0 |
0.13 |
| Id Reaction |
0 |
0.13 |
| Intravenous |
0 |
0.13 |
| Liver |
0 |
0.13 |
| Lymphoma |
0 |
0.6 |
| Patient Safety |
0 |
0.13 |
| Thromboembolism |
0 |
0.13 |